Vasomedical WKN 882846 Rebounder?!

immer wieder schön zu sehen das wenn was geht es richtig geht
ich bleibe in der Hoffnung bald die 0.50 cent hinter uns zu lassen.

@Bergkämpfer
Dein Post vom 19.02 mit 6 Dollar klingt zwar echt krass aber bis Jahresende auf 1,80$ würde mir persönlich schon ein "schönes" Weihnachten bereiten ;)

@all

Good luck and have fun  

http://www.vasomedical.com/blog/2014/03/05/...erapy-week-goes-global/

1,2mrd Menschen sind kein kleiner Markt. :)

dazu Russland, Europa und neuerdings der Nahe Osten sowie Afrika. Aber Mr. Market braucht wohl harte Zahlen (März/April) oder einen besseren Markt in den USA.

 

zwei 30k Blöcke kurz vor Handelsschluss aus dem ask genibbelt.
viel liegt da nun nicht mehr rum.

Würde auch sehr schön zum Chart passen..  

auch schön.

https://www.facebook.com/vasomedical  

laut etrade ist das ask bei 0,55 bid 0,41... . Vorbörslich wird hier wild rumgetaxt.
der chart + volumen lassen auf heute hoffen.
^^

431 "gefällt mir"?, nice. sind schon ein paar mehr geworden seit meinem letzten Besuch.  

Leg up? JO!  

die 0,48 ham leider nich lange gehalten. dafür aber ordentliches Volumen.  

schöne entwicklung heute, und das ask wird immer kleiner :)  

 

soweit mein plan aufgeht, werde ich am freitag den 28.03.14 das letzte mal bei vaso aufstocken. ich denke, dass wir nach den zahlen endgültig den bereich <0.5 verlassen haben werden- vll ist auch der aktuelle anstieg in volumen und preis bedingt durch das durchsickern von informationen über vermeintlich sehr gute ergebnisse des letzten jahres.

ich hoffe ihr habt nen sack voll vaso shares akkumuliert und freut euch wie ich auf unsere belohnung fürs lange durchhalten. good luck to all longs. stay tuned.  

Vasomedical Announces Biox's MobiCare™ Wireless Patient Monitors Receives Marketing Approval in China

13:05 17.03.14

PR Newswire

WESTBURY, N.Y., March 17, 2014

WESTBURY, N.Y., March 17, 2014 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that its wholly owned subsidiary Biox Instruments Co. Ltd., based in Wuxi, China, has received approval from the Chinese Food and Drug Administration (CFDA) to begin marketing its new MobiCare Wireless Patient Monitors in China.

MobiCare Wireless Patient Monitor is a vital signs monitoring system that acquires and displays multiple physiological signals, including electrocardiogram (ECG), blood pressure, respiration, peripheral capillary oxygen saturation (SpO2), body temperature, as well as provides real-time detection and alerts for certain abnormalities in these vital signs.  Unlike traditional bedside patient monitoring systems, the MobiCare system transmits patient signals wirelessly to a touch-screen tablet receiver or a bedside monitor.  The MobiCare system's wireless connectivity untethers patients from the bedside monitor allowing them movement within a certain range.  The Biox MobiCare system will first be sold to hospitals in China as a new type of bedside patient monitor, in order to cultivate acceptance of the technology and set the stage for future introduction into the fast growing global home care market.

"Our MobiCare system is a breakthrough into the relatively mature but still growing market of vital sign monitoring devices.  More importantly, with its current configuration and planned future derivatives, the MobiCare system provides a natural bridge to telemedicine and home care systems, putting us in a strong position in these healthcare markets of the future," commented Dr. Jun Ma, President and CEO of Vasomedical.  "This innovative device is another example of making good on our promise to deliver advanced quality products at affordable prices so that patients all over the world may benefit as we continue to build shareholder value in our company."

The MobiCare prototypes were first exhibited in November 2013 at CMEF Autumn 2013 in Xiamen, China and at MEDICA 2013 in Dusseldorf, Germany, and then at Arab Health 2014 in Dubai, UAE in January 2014.  Based on the positive feedback from attendees at these events, the Company is preparing applications for CE marking and US FDA clearance.

 

immerhin  

http://finance.yahoo.com/news/...rt-fourth-quarter-end-120000802.html

und am 28. gibt es nen schub fürs depot? glta longs :)

 

Ich bin ja mal sehr gespannt auf die nächste Woche. Durch die Zahlen sollte ja mal wieder ordentlich Schwung rein kommen. Auf eine hoffentlich gut Woche mit neuen Hochs :-)  

ich denke wir werden nächste Woche schöne Buchgewinne haben, die man aber einfach noch nicht realisieren möchte. freitag ist der tag, an dem sich eine 5 jahre andauernde treue zur aktie auszahlen wird. was für eine woche. POET TEWI ANX.TO CAPC und vor allem: VASO!
es wird spannend.  

Presentation 3/29-31

The Effects of EECP® Therapy on Vascular Function and Hypercholesterolemia to be Presented at ACC.14 in Washington, DC



WESTBURY, N.Y., March 21, 2014 -Vasomedical, Inc. (“Vasomedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for non-invasive cardiology – including EECP® Therapy systems, the gold standard of ECP therapy, and ECG Holter and Ambulatory Blood Pressure monitoring products – today announced that an abstract titled “EECP Improves Vascular Function And Status In Hypercholesterolemic Subjects with Subclinical Atherosclerosis” has been selected for presentation at the 63rd Scientific Sessions of the American College of Cardiology (ACC) to be held in Washington, DC from March 29-31, 2014.

The authors from Sun Yat Sen University and the State University of New York at Stony Brook researched the effect of EECP Therapy on vascular markers in patients with hypocholesterolemia, the presence of high levels of cholesterol in their blood, but whose atherosclerosis is in an early stage before any symptoms have been noted, called subclinical atherosclerosis.

The abstract (Poster #155) will be presented on Saturday, March 29, 2014 from 10:00 to 10:45 AM in Hall C of the Walter E. Washington Convention Center.

Using common carotid artery intima-media thickness (CCA-IMT) of greater than 1 mm or the presence of plaque on carotid ultrasound clips and no reported symptoms of coronary artery disease as the selection criteria, the subclinical atherosclerotic subjects were randomized into two groups: the EECP Group which underwent the standard EECP regimen of one hour per day for seven weeks while taking Simvastatin 40 mg and the Control Group, which only took Simvastatin 40 mg every day. The researchers evaluated vascular status and functions using CCA-IMT, flow-mediated dilation (FMD) of the brachial artery and pulse wave velocity (PWV) of the subjects at baseline and after seven week

 

At the beginning of the study there were no significant differences between the two groups. At the end of the study, the LDL levels of the EECP Group were slightly, though not significantly, less than those of the patients in the control group. However, the study reported that the EECP Group had an 11.63 percent reduction of CCA-IMT and a 39.78 percent increase in FMD, demonstrating significant differences in improvement over those changes reported in the control group.

“As physicians, we are well trained and experienced in understanding diseases and providing effective treatments. Our challenge in the future is also how to prevent or slow down the progression of disease. In this study we wanted to explore the use of EECP Therapy to improve endothelial dysfunction by increasing the shear stress on vessel walls,” stated Dr. William Lawson, Professor, Department of Internal Medicine, and Chief of Cardiology and Director of the Heart Institute at Stony Brook.

He continued, ”This study demonstrated that EECP improves carotid artery wall thickness, the primary marker of early atherosclerosis, and vascular remodeling as well as endothelial function, suggesting that EECP is a possible therapeutic strategy for the prevention of atherosclerotic disease.”
Those wishing to see a live demonstration of EECP Therapy may visit Booth # 3003 in the Expo Hall. Exhibits open Saturday, March 29th through Monday, March 31st at 9:30 AM. The exhibits close Saturday and Sunday at 4:30 PM and 2:30 PM on Monday.  

ich sag doch nach den zahlen sind wir durch die 0,5durch. jeeeeehaaa. peng peng peng.  

so einen sanften und steten anstieg bei steigendem volumen hab ich bei Vaso noch nicht gesehen. Scheint als wollten noch welche vor den Zahlen (morgen) im Boot sein.
 

Die 50 Cent haben wir jetzt schon mal, jetzt können wir uns an dem Rest des Dollars heranpirschen ;-)  

http://finance.yahoo.com/news/...ancial-results-fourth-131500142.html

 

und bin echt sauer  

"every dollar of deferred revenues stays for 2 dollars in potential income ones the underlying equipment or service is delivered"

das bedeutet da schlummert ein potential von 36mio an einkünften von denen 24mio in den nächsten 12monaten kommen können. da nur 6 der 18 mio$ long term deferred revenues sind.

sentiment: hold or add  

Reply from Investor Relations Regarding Concerns: Part I

John,

Vasomedical values the support of its shareholders and believes effective, candid communication can help sustain and increase their support. Your recent inquiry to the Company has been forwarded to our attention, and I would like to take the opportunity to address some concerns and clarify its position.

Regarding Vasomedical’s financial results reported on March 27th, management was pleased by the performance of the Company and its subsidiaries for 2013, in which total revenues grew by 12.5% and the VasoHealthcare subsidiary reached the highest commission rate under its agreement with GEHC. However, this performance wasn’t entirely reflected in our revenue which is only recognized on delivery of the equipment, due to timing of equipment deliveries to customers by GE Healthcare during the fourth quarter of 2013. This is reflected by our deferred revenue on the balance sheet, which increased to $18.0 million in 2013 compared with $15.6 million for 2012. In addition, it is important to consider the increase in cash to $13.8 million as of February 28, 2014, compared to $11.5 million as of December 31, 2012, even after the Company used approximately $1.8 million in its share repurchase program during 2013.

Regarding the EECP business, many shareholders, as well as some members of the board and management team were drawn to Vasomedical because of this technology. The Company remains committed to the success of EECP technology and intends to continue working diligently and intelligently based on its best judgment for the benefit of all stakeholders.

Over the last several years, the Company has made considerable investments into the EECP business and has attained some successes in various areas, as you may have been aware through public announcements and other information channels.

Nevertheless, EECP still experiences significant adoption challenges and certain regulatory hurdles, particularly with regard to applications as well as reimbursement beyond refractory angina. As such, management has informed shareholders that the market for EECP will remain soft, and this is exactly the reason they embarked on a diversification strategy that could allow the Company to expand at the same time as it’s weathering the time-consuming battle for broad acceptance of EECP.

In the interim, the relative contribution of EECP to our total revenue may decrease to the extent management is successful in executing its growth and diversification strategy.

Regarding the stock price and shares outstanding, management is very aware of the recent fluctuations in the Company’s stock price. While management does not usually comment on the stock price, it believes that two factors may have been among the factors driving the latest trading activity: the interpretation of the financial results for year ended December 31, 2013, which is discussed above, and current trends in the financial markets affecting life science stocks in general  

Over the past nine months the Company's stock price has gone from $0.18 to around $0.30, a 65% appreciation. While shareholders have seen the stock as high as $0.50 during this period, there is currently a broad sell-off of stocks in the life science sector, which is hitting micro-cap companies especially hard. While shareholders including members of the board and management are certainly disappointed by this more recent trend, the Company firmly believes that its financial performance in 2013 and previously announced expectation to achieve profitability in 2014 are positive factors on a going forward basis.

Some of the Company’s shareholders, especially those who did not live through its recent history, questioned why the number of outstanding stock increased so much. There were two major events that led to the significant increase in shares outstanding. When Kerns Manufacturing and Living Data Technology stepped in to rescue the Company from the verge of bankruptcy, about 40 million shares of stock and 4 million shares of warrants were issued in 2007 and 2008 in exchange for their investment, including cash, business transfer and equipment. In 2010, when the Company started the sales representation business with GEHC, Vasomedical raised over $5 million of capital by issuing interest bearing preferred stock, all of which were subsequently converted to common shares in 2011, amounting to over 30 million shares of stock. We believe that both of these events have been positive game changers for the Company.

I hope my comments above addressed some, if not all, of your concerns and presented a clearer picture for you. The Company intends to continue to make investments into its businesses with the greatest current growth opportunity and what is believed to be limited risk. In addition to the current operations, management continues to aggressively seek accretive acquisitions and partnerships with the intention of continuing to propel the Company’s growth and us